Stock analysts at StockNews.com started coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a report released on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.
Separately, Brookline Capital Management lowered shares of Biocept from a “buy” rating to a “hold” rating in a report on Friday, January 6th.
Biocept Price Performance
Shares of NASDAQ BIOC opened at $0.24 on Friday. The stock has a market cap of $4.02 million, a price-to-earnings ratio of -0.24 and a beta of 1.01. Biocept has a 52 week low of $0.24 and a 52 week high of $2.43. The company’s 50-day moving average price is $0.51 and its 200 day moving average price is $0.68. The company has a current ratio of 5.13, a quick ratio of 4.86 and a debt-to-equity ratio of 0.04.
Institutional Investors Weigh In On Biocept
Biocept, Inc is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.
- Get a free copy of the StockNews.com research report on Biocept (BIOC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.